Economic burden of antibiotic resistance: How much do we really know?

Clinical Microbiology and Infection

Volumn 20, Issue 10, 2014, Pages 973-979

  Gandra, S ^a   Barter, D M ^a   Laxminarayan, R ^a,b,c  

^a Economics and Policy   (United States)

^b PUBLIC HEALTH FOUNDATION OF INDIA   (India)

^c PRINCETON UNIVERSITY   (United States)

Author keywords

Antibiotic resistance; Attributable morbidity and mortality; Economics

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BLOODSTREAM INFECTION; COHORT ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; ECONOMIC EVALUATION; EXPOSURE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH PRACTITIONER; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; LENGTH OF STAY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; ECONOMICS; STATISTICAL MODEL;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMIC;

EID: 84912531425     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12798     Document Type: Review

References (87)

1. Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. JAMA 1999; 281: 61-66.
2. Jayachandran S, Lleras-Muney A, Smith KV. Modern medicine and the twentieth century decline in mortality: evidence on the impact of sulfa drugs. Am Econ J Appl Econ 2010; 2: 118-146.
3. Spellberg B, Blaser M, Guidos RJ et al. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 2011; 52: S397-428.
4. Carlet J, Jarlier V, Harbarth S, Voss A, Goossens H, Pittet D. Ready for a world without antibiotics? The pensieres antibiotic resistance call to action. Antimicrob Resist Infect Control 2012; 1: 11.
5. World Health Organization. Antimicrobial resistance: global report on surveillance 2014. Geneva: WHO.
6. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003; 36: 1433-1437.
7. Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther 2008; 6: 751-763.
8. Blot S, Depuydt P, Vandewoude K, De Bacquer D. Measuring the impact of multidrug resistance in nosocomial infection. Curr Opin Infect Dis 2007; 20: 391-396.
9. Howard D, Cordell R, McGowan JE et al. Measuring the economic costs of antimicrobial resistance in hospital settings: summary of the Centers for Disease Control and Prevention-Emory workshop. Clin Infect Dis 2001; 33: 1573-1578.
10. de Kraker ME, Wolkewitz M, Davey PG et al. Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother 2011; 66: 398-407.
11. de Kraker ME, Wolkewitz M, Davey PG et al. Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother 2011; 55: 1598-1605.
12. Neidell MJ, Cohen B, Furuya Y et al. Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. Clin Infect Dis 2012; 55: 807-815.
13. De Angelis G, Murthy A, Beyersmann J, Harbarth S. Estimating the impact of healthcare-associated infections on length of stay and costs. Clin Microbiol Infect 2010; 16: 1729-1735.
14. Beyersmann J, Wolkewitz M, Schumacher M. The impact of time-dependent bias in proportional hazards modelling. Stat Med 2008; 27: 6439-6454.
15. Barnett AG, Beyersmann J, Allignol A, Rosenthal VD, Graves N, Wolkewitz M. The time-dependent bias and its effect on extra length of stay due to nosocomial infection. Value Health 2011; 14: 381-386.
16. Lambert ML, Suetens C, Savey A et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. Lancet Infect Dis 2011; 11: 30-38.
17. Wolkewitz M, Frank U, Philips G, Schumacher M, Davey P. Mortality associated with in-hospital bacteraemia caused by Staphylococcus aureus: a multistate analysis with follow-up beyond hospital discharge. J Antimicrob Chemother 2011; 66: 381-386.
18. Macedo-Vinas M, De Angelis G, Rohner P et al. Burden of meticillin-resistant Staphylococcus aureus infections at a Swiss university hospital: excess length of stay and costs. J Hosp Infect 2013; 84: 132-137.
19. Stewardson A, Fankhauser C, De Angelis G et al. Burden of bloodstream infection caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae determined using multistate modeling at a Swiss university hospital and a nationwide predictive model. Infect Control Hosp Epidemiol 2013; 34: 133-143.
20. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36: 53-59.
21. Rubin RJ, Harrington CA, Poon A, Dietrich K, Greene JA, Moiduddin A. The economic impact of Staphylococcus aureus infection in New York city hospitals. Emerg Infect Dis 1999; 5: 9-17.
22. McHugh CG, Riley LW. Risk factors and costs associated with methicillin-resistant Staphylococcus aureus bloodstream infections. Infect Control Hosp Epidemiol 2004; 25: 425-430.
23. Lee NY, Lee HC, Ko NY et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 2007; 28: 713-719.
24. Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol 1999; 20: 408-411.
25. Engemann JJ, Carmeli Y, Cosgrove SE et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003; 36: 592-598.
26. Kopp BJ, Nix DE, Armstrong EP. Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections. Ann Pharmacother 2004; 38: 1377-1382.
27. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 2005; 52: 113-122.
28. Reed SD, Friedman JY, Engemann JJ et al. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2005; 26: 175-183.
29. Maclayton DO, Suda KJ, Coval KA, York CB, Garey KW. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/ml and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther 2006; 28: 1208-1216.
30. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005; 26: 166-174.
31. Shorr AF, Tabak YP, Gupta V, Johannes RS, Liu LZ, Kollef MH. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Crit Care (Lond) 2006; 10: R97.
32. Lipsky BA, Weigelt JA, Gupta V, Killian A, Peng MM. Skin, soft tissue, bone, and joint infections in hospitalized patients: epidemiology and microbiological, clinical, and economic outcomes. Infect Control Hosp Epidemiol 2007; 28: 1290-1298.
33. Weigelt JA, Lipsky BA, Tabak YP, Derby KG, Kim M, Gupta V. Surgical site infections: causative pathogens and associated outcomes. Am J Infect Control 2010; 38: 112-120.
34. Filice GA, Nyman JA, Lexau C et al. Excess costs and utilizatio associated with methicillin resistance for patients with Staphylococcus aureus infection. Infect Control Hosp Epidemiol 2010; 31: 365-373.
35. Ben-David D, Novikov I, Mermel LA. Are there differences in hospital cost between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillin-susceptible S. aureus bloodstream infection?. Infect Control Hosp Epidemiol 2009; 30: 453-460.
36. Park SY, Son JS, Oh IH, Choi JM, Lee MS. Clinical impact of methicillin-resistant Staphylococcus aureus bacteremia based on propensity scores. Infection 2011; 39: 141-147.
37. Ott E, Bange FC, Reichardt C et al. Costs of nosocomial pneumonia caused by meticillin-resistant Staphylococcus aureus. J Hosp Infect 2010; 76: 300-303.
38. Taneja C, Haque N, Oster G et al. Clinical and economic outcomes in patients with community-acquired Staphylococcus aureus pneumonia. J Hosp Med 2010; 5: 528-534.
39. Rubio-Terres C, Garau J, Grau S, Martinez-Martinez L, Cast Resistance Study Group. Cost of bacteraemia caused by methicillin-resistant vs. methicillin-susceptible Staphylococcus aureus in Spain: a retrospective cohort study. Clin Microbiol Infect 2010; 16: 722-728.
40. Webb M, Riley LW, Roberts RB. Cost of hospitalization for and risk factors associated with vancomycin-resistant Enterococcus faecium infection and colonization. Clin Infect Dis 2001; 33: 445-452.
41. Song X, Srinivasan A, Plaut D, Perl TM. Effect of nosocomial vancomycin-resistant enterococcal bacteremia on mortality, length of stay, and costs. Infect Control Hosp Epidemiol 2003; 24: 251-256.
42. Carmeli Y, Eliopoulos G, Mozaffari E, Samore M. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med 2002; 162: 2223-2228.
43. Gearhart M, Martin J, Rudich S et al. Consequences of vancomycin-resistant enterococcus in liver transplant recipients: a matched control study. Clin Transplant 2005; 19: 711-716.
44. Bach PB, Malak SF, Jurcic J et al. Impact of infection by vancomycin-resistant enterococcus on survival and resource utilization for patients with leukemia. Infect Control Hosp Epidemiol 2002; 23: 471-474.
45. Pelz RK, Lipsett PA, Swoboda SM et al. Vancomycin-sensitive and vancomycin-resistant enterococcal infections in the ICU: attributable costs and outcomes. Intensive Care Med 2002; 28: 692-697.
46. Stosor V, Peterson LR, Postelnick M, Noskin GA. Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch Intern Med 1998; 158: 522-527.
47. Montecalvo MA, Jarvis WR, Uman J et al. Costs and savings associated with infection control measures that reduced transmission of vancomycin-resistant enterococci in an endemic setting. Infect Control Hosp Epidemiol 2001; 22: 437-442.
48. Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999; 159: 1127-1132.
49. Lautenbach E, Synnestvedt M, Weiner MG et al. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect Control Hosp Epidemiol 2010; 31: 47-53.
50. Lautenbach E, Synnestvedt M, Weiner MG et al. Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. Infect Control Hosp Epidemiol 2009; 30: 1186-1192.
51. Wilson SJ, Knipe CJ, Zieger MJ et al. Direct costs of multidrug-resistant Acinetobacter baumannii in the burn unit of a public teaching hospital. Am J Infect Control 2004; 32: 342-344.
52. Young LS, Sabel AL, Price CS. Epidemiologic, clinical, and economic evaluation of an outbreak of clonal multidrug-resistant Acinetobacter baumannii infection in a surgical intensive care unit. Infect Control Hosp Epidemiol 2007; 28: 1247-1254.
53. Vandijck DM, Blot SI, Decruyenaere JM et al. Costs and length of stay associated with antimicrobial resistance in acute kidney injury patients with bloodstream infection. Acta Clin Belg 2008; 63: 31-38.
54. Evans HL, Lefrak SN, Lyman J et al. Cost of gram-negative resistance. Crit Care Med 2007; 35: 89-95.
55. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2006; 50: 1257-1262.
56. Tumbarello M, Spanu T, Di Bidino R et al. Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother 2010; 54: 4085-4091.
57. MacVane SH, Tuttle LO, Nicolau DP. Impact of extended-spectrum beta-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection. J Hosp Med 2014; 9: 232-238.
58. Cohen B, Larson EL, Stone PW, Neidell M, Glied SA. Factors associated with variation in estimates of the cost of resistant infections. Med Care 2010; 48: 767-775.
59. European Centre for Disease Control, European Medicines Agency. The bacterial challenge: time to react. A call to narrow the gap between multi-drug resistant bacteria in the EU and the development of new antibacterial agents 2009. Stockholm: European Centre for Disease Prevention and Control.
60. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006; 42(suppl 2): S82-S89.
61. The Brooklyn Antibiotic Resistance Task Force. The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudmonas aeruginosa on length of hospital stay. Infect Control Hosp Epidemiol 2002; 23: 106-108.
62. Plowman R, Graves N, Griffin MA et al. The rate and cost of hospital-acquired infections occurring in patients admitted to selected specialties of a district general hospital in England and the national burden imposed. J Hosp Infect 2001; 47: 198-209.
63. Shorr AF. Epidemiology and economic impact of meticillin-resistant Staphylococcus aureus: review and analysis of the literature. PharmacoEconomics 2007; 25: 751-768.
64. Roberts RR, Hota B, Ahmad I et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 2009; 49: 1175-1184.
65. de Kraker ME, Davey PG, Grundmann H. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Med 2011; 8: e1001104.
66. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005; 18: 657-686.
67. Mikulska M, Viscoli C, Orasch C et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect 2014; 68: 321-331.
68. Men TY, Wang JN, Li H et al. Prevalence of multidrug-resistant gram-negative bacilli producing extended-spectrum beta-lactamases (ESBLs) and ESBL genes in solid organ transplant recipients. Transpl Infect Dis 2013; 15: 14-21.
69. van Delden C, Blumberg EA. Multidrug resistant gram-negative bacteria in solid organ transplant recipients. Am J Transplant 2009; 9: A27-34.
70. Bodro M, Sabe N, Tubau F et al. Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients. Transplantation 2013; 96: 843-849.
71. Sganga G, Spanu T, Bianco G et al. Bacterial bloodstream infections in liver transplantation: etiologic agents and antimicrobial susceptibility profiles. Transplant Proc 2012; 44: 1973-1976.
72. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008; 29: 1099-1106.
73. Le Doare K, Bielicki J, Heath PT, Sharland M. Systematic review of antibiotic resistance rates among gram-negative bacteria in children with sepsis in resource-limited countries. J Pediatr Infect Dis Soc 2014; doi: 10.1093/jpids/piu014.
74. Waters D, Jawad I, Ahmad A et al. Aetiology of community-acquired neonatal sepsis in low and middle income countries. J Glob Health 2011; 1: 154-170.
75. Viswanathan R, Singh AK, Ghosh C, Dasgupta S, Mukherjee S, Basu S. Profile of neonatal septicaemia at a district-level sick newborn care unit. J Health Popul Nutr 2012; 30: 41-48.
76. Khan E, Ejaz M, Zafar A et al. Increased isolation of ESBL producing Klebsiella pneumoniae with emergence of carbapenem resistant isolates in Pakistan: report from a tertiary care hospital. J Pak Med Assoc 2010; 60: 186-190.
77. Kayange N, Kamugisha E, Mwizamholya DL, Jeremiah S, Mshana SE. Predictors of positive blood culture and deaths among neonates with suspected neonatal sepsis in a tertiary hospital, Mwanza-Tanzania. BMC Pediatr 2010; 10: 39.
78. Blomberg B, Jureen R, Manji KP et al. High rate of fatal cases of pediatric septicemia caused by gram-negative bacteria with extended-spectrum beta-lactamases in Dar Es Salaam, Tanzania. J Clin Microbiol 2005; 43: 745-749.
79. Smith R, Coast J. The true cost of antimicrobial resistance. BMJ 2013; 346: f1493.
80. Smith RD, Yago M, Millar M, Coast J. Assessing the macroeconomic impact of a healthcare problem: the application of computable general equilibrium analysis to antimicrobial resistance. J Health Econ 2005; 24: 1055-1075.
81. Smith RD, Yago M, Millar M, Coast J. A macroeconomic approach to evaluating policies to contain antimicrobial resistance: a case study of methicillin-resistant Staphylococcus aureus (MRSA). Appl Health Econ Health Policy 2006; 5: 55-65.
82. Eber MR, Laxminarayan R, Perencevich EN, Malani A. Clinical and economic outcomes attributable to health care-associated sepsis and pneumonia. Arch Intern Med 2010; 170: 347-353.
83. Schulgen G, Kropec A, Kappstein I, Daschner F, Schumacher M. Estimation of extra hospital stay attributable to nosocomial infections: heterogeneity and timing of events. J Clin Epidemiol 2000; 53: 409-417.
84. Thom KA, Shardell MD, Osih RB et al. Controlling for severity of illness in outcome studies involving infectious diseases: impact of measurement at different time points. Infect Control Hosp Epidemiol 2008; 29: 1048-1053.
85. Rottier WC, Ammerlaan HS, Bonten MJ. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother 2012; 67: 1311-1320.
86. Beyersmann J, Gastmeier P, Wolkewitz M, Schumacher M. An easy mathematical proof showed that time-dependent bias inevitably leads to biased effect estimation. J Clin Epidemiol 2008; 61: 1216-1221.
87. Zhang W, Bansback N, Anis AH. Measuring and valuing productivity loss due to poor health: a critical review. Soc Sci Med 1982; 2011: 185-192.